Biogen
BIIB
$257.01
Share price
-0.32%
Change (1 day)
-2.75%
Change (1 year)
Categories
Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
Revenue for Biogen (BIIB)
Revenue in 2023 (TTM): $9.97 B
According to Biogen's latest financial reports the company's current revenue (TTM) is $9.97 B. In 2022 the company made a revenue of $10.17 B a decrease over the years 2021 revenue that were of $10.98 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Biogen from 2001 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $9.97 B | -1.98% |
| 2022 | $10.17 B | -7.36% |
| 2021 | $10.98 B | -18.32% |
| 2020 | $13.44 B | -6.49% |
| 2019 | $14.37 B | 6.88% |
| 2018 | $13.45 B | 9.61% |
| 2017 | $12.27 B | 7.21% |
| 2016 | $11.44 B | 6.36% |
| 2015 | $10.76 B | 10.93% |
| 2014 | $9.70 B | 39.97% |
| 2013 | $6.93 B | 32.58% |
| 2012 | $5.22 B | 3.57% |
| 2011 | $5.04 B | 7.04% |
| 2010 | $4.71 B | 7.75% |
| 2009 | $4.37 B | 6.83% |
| 2008 | $4.09 B | 29.19% |
| 2007 | $3.17 B | 69.41% |
| 2006 | $1.87 B | 9.25% |
| 2005 | $1.71 B | 7.38% |
| 2004 | $1.59 B | 134.96% |
| 2003 | $0.67 B | -40.86% |
| 2002 | $1.14 B | 10.06% |
| 2001 | $1.04 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $93.76 B | 840.30% | 🇺🇸 USA |
 Pfizer PFE | $77.94 B | 681.67% | 🇺🇸 USA |
 AbbVie ABBV | $56.02 B | 461.83% | 🇺🇸 USA |
 Amgen AMGN | $26.58 B | 166.58% | 🇺🇸 USA |
 Sanofi SNY | $48.63 B | 387.77% | 🇫🇷 France |
 Gilead Sciences GILD | $27.38 B | 174.60% | 🇺🇸 USA |
 Illumina ILMN | $4.46 B | -55.26% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $0.11 B | -98.83% | 🇺🇸 USA |
 Qiagen QGEN | $1.97 B | -80.16% | 🇳🇱 Netherlands |
 Bio-Rad Laboratories BIO | $2.76 B | -72.23% | 🇺🇸 USA |